Five Prime Therapeutics (FPRX) Stock: Weak On High Volume Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Five Prime Therapeutics ( FPRX) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Five Prime Therapeutics as such a stock due to the following factors:

  • FPRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $9.1 million.
  • FPRX has traded 98,817 shares today.
  • FPRX is trading at 6.94 times the normal volume for the stock at this time of day.
  • FPRX is trading at a new low 3.00% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in FPRX with the Ticky from Trade-Ideas. See the FREE profile for FPRX NOW at Trade-Ideas

If you liked this article you might like

Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers

Today Five Prime Therapeutics (FPRX) Hits New Lifetime High

Five Prime Therapeutics (FPRX) Is Today's Strong On High Volume Stock

3 Small Biotechs That Look Very Healthy

3 Small Biotechs That Look Very Healthy

Five Prime Therapeutics (FPRX) Is Today's Perilous Reversal Stock